Cerevel Therapeutics Holdings Inc (CERE)
42.25
-0.13
(-0.31%)
USD |
NASDAQ |
Mar 28, 16:00
42.28
+0.03
(+0.07%)
After-Hours: 20:00
Cerevel Therapeutics Holdings Cash from Financing (TTM): 548.62M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 548.62M |
September 30, 2023 | 42.38M |
June 30, 2023 | 619.82M |
March 31, 2023 | 622.02M |
December 31, 2022 | 623.19M |
September 30, 2022 | 623.38M |
June 30, 2022 | 432.32M |
Date | Value |
---|---|
March 31, 2022 | 425.46M |
December 31, 2021 | 423.60M |
September 30, 2021 | 841.36M |
June 30, 2021 | 476.06M |
March 31, 2021 | 441.58M |
December 31, 2020 | 440.84M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
42.38M
Minimum
Sep 2023
841.36M
Maximum
Sep 2021
504.66M
Average
476.06M
Median
Jun 2021
Cash from Financing (TTM) Benchmarks
AbbVie Inc | -17.22B |
Immunogen Inc (DELISTED) | 495.80M |
Icosavax Inc (DELISTED) | 78.07M |
Karuna Therapeutics Inc (DELISTED) | 483.37M |
Rain Oncology Inc (DELISTED) | 53.08M |